Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 93.00 | |
5 mg | In stock | $ 217.00 | |
10 mg | In stock | $ 321.00 | |
25 mg | In stock | $ 542.00 | |
50 mg | In stock | $ 779.00 | |
100 mg | In stock | $ 1,090.00 | |
500 mg | In stock | $ 2,180.00 |
Description | Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR. |
Targets&IC50 | EGFR (L861Q):0.423 nM, EGFR (L858R):0.563 nM, EGFR (WT):0.611 nM, EGFR (T790M):45.2 nM |
In vivo | Larotinib (250, 300, 350 mg; oral; once daily; patients) demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.[1] |
Molecular Weight | 488.94 |
Formula | C24H26ClFN4O4 |
CAS No. | 1438072-11-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Larotinib 1438072-11-7 Angiogenesis Immunology/Inflammation JAK/STAT signaling NF-Κb Tyrosine Kinase/Adaptors EGFR BTK Tyrosine Kinases IRAK inhibitor inhibit